T2 Biosystems, Inc. (TTOO)
Chart Events
Performance Outlook
| Previous Close | 2.4800 |
| Open | 2.5700 |
| Bid | 2.2900 x 3200 |
| Ask | 2.3000 x 3200 |
| Day's Range | 2.2600 - 2.5800 |
| 52 Week Range | 0.2350 - 3.7900 |
| Volume | 5,653,699 |
| Avg. Volume | 11,968,062 |
| Market Cap | 341.941M |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5290 |
| Earnings Date | Mar 04, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.18 |
Fair Value
Related Research
- GlobeNewswire
T2 Biosystems to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
LEXINGTON, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2020 after market close on Thursday, March 4, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 877-407-9208 (U.S.) or 201-493-6784 (International) five to ten minutes prior to the start time. About T2 Biosystems:T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens. Media Contact:Gina Kent, Vault Communicationsgkent@vaultcommunications.com610-455-2763 Investor Contact:Philip Trip Taylor, Gilmartin Groupphilip@gilmartinIR.com415-937-5406
- GlobeNewswire
T2 Biosystems to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference
LEXINGTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference. Management is scheduled to present Friday, February 19, 2021 at 10:00am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com. About T2 BiosystemsT2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens. Media Contact:Gina Kent, Vault Communicationsgkent@vaultcommunications.com 610-455-2763 Investor Contact:Philip Trip Taylor, Gilmartin Groupphilip@gilmartinIR.com 415-937-5406
- Motley Fool
Why T2 Biosystems Stock Soared Today
Shares of T2 Biosystems (NASDAQ: TTOO) jumped on Friday after the healthcare diagnostics specialist said its testing panel could detect the new strain of the coronavirus first identified in Brazil. T2 Biosystems has now confirmed that its T2SARS-CoV-2 Panel can detect many different coronavirus strains, including the variants first identified in the U.K., South Africa, and Brazil. A recent evaluation of more than 42,000 genome sequences for the novel coronavirus showed that T2 Biosystems' panel should detect 99.99% of all currently identified SARS-CoV-2 viruses.
